Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
MicroRNAs01:22

MicroRNAs

3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Lncrna Ddx11-as1 Promotes Breast Cancer Progression By Targeting The Mir-30c-5p/mtdh Axis

LncRNA DDX11-AS1 promotes breast cancer progression by targeting the miR-30c-5p/MTDH axis

Yanting Li1, Mengsi Zhou1, Liu Yang2

  • 1Department of Breast Surgery, the Second Hospital of Hebei Medical University, Shijiazhuang, 050051, China.

Scientific Reports
|November 5, 2024

Related Experiment Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.6K
Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

6.7K
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
00:07

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.2K

View abstract on PubMed

Summary
This summary is machine-generated.

The long noncoding RNA DDX11-AS1 promotes breast cancer (BC) progression by stabilizing MTDH through interaction with miR-30c-5p. This axis highlights DDX11-AS1 as a potential therapeutic target for BC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Long noncoding RNAs (lncRNAs) are implicated in cancer development.
  • The role of ceRNAs in breast cancer (BC) prognosis requires further investigation.
  • Understanding lncRNA functions is crucial for identifying novel cancer biomarkers and therapies.

Purpose of the Study:

  • To investigate the role of lncRNA DDX11-AS1 in breast cancer (BC) progression.
  • To elucidate the molecular mechanism underlying DDX11-AS1's function in BC.
  • To evaluate DDX11-AS1 as a potential biomarker and therapeutic target for BC.

Main Methods:

  • Bioinformatics analysis of public microarray data to identify upregulated lncRNAs in BC.
  • RT-qPCR to validate DDX11-AS1 expression in BC tissues.
Keywords:
Breast cancerDDX11-AS1MetadherinMiR-30c-5p

Related Experiment Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.6K
Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

6.7K
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
00:07

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.2K
  • In vitro assays to assess the impact of DDX11-AS1 knockdown on BC cell proliferation, migration, and invasion.
  • Mechanistic studies involving miRNA and target gene analysis to explore the regulatory pathway.

    • Main Results:

    • DDX11-AS1 was found to be upregulated in BC tissues and correlated with advanced pathological grade and lymph node metastasis.
    • Knockdown of DDX11-AS1 significantly inhibited BC cell proliferation, migration, and invasion.
    • DDX11-AS1 promotes BC progression by sponging miR-30c-5p, leading to increased MTDH expression.
    • miR-30c-5p was downregulated, and MTDH was upregulated in BC tissues and cells.

    Conclusions:

    • The lncRNA DDX11-AS1/miR-30c-5p/MTDH axis is associated with breast cancer progression.
    • DDX11-AS1 acts as a tumor promoter in BC by regulating the miR-30c-5p/MTDH pathway.
    • DDX11-AS1 represents a potential diagnostic biomarker and therapeutic target for breast cancer.
    Progression